Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32,360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.
Mehnert JM, Tan AR, Moss R, Poplin E, Stein MN, Sovak M, Levinson K, Lin H, Kane M, Gounder M, Lin Y, Shih WJ, White E, Rubin EH, Karantza V. Mehnert JM, et al. Among authors: lin y, lin h. Mol Cancer Ther. 2011 Aug;10(8):1509-19. doi: 10.1158/1535-7163.MCT-10-0944. Epub 2011 Jun 16. Mol Cancer Ther. 2011. PMID: 21680752 Free PMC article. Clinical Trial.
Activated matriptase as a target to treat breast cancer with a drug conjugate.
Rather GM, Lin SY, Lin H, Banach-Petrosky W, Hirshfield KM, Lin CY, Johnson MD, Szekely Z, Bertino JR. Rather GM, et al. Among authors: lin sy, lin cy, lin h. Oncotarget. 2018 May 25;9(40):25983-25992. doi: 10.18632/oncotarget.25414. eCollection 2018 May 25. Oncotarget. 2018. PMID: 29899836 Free PMC article.
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.
Mehnert JM, Kaveney AD, Malhotra J, Spencer K, Portal D, Goodin S, Tan AR, Aisner J, Moss RA, Lin H, Bertino JR, Gibbon D, Doyle LA, White EP, Stein MN. Mehnert JM, et al. Among authors: lin h. Cancer Chemother Pharmacol. 2019 Oct;84(4):899-907. doi: 10.1007/s00280-019-03919-x. Epub 2019 Aug 28. Cancer Chemother Pharmacol. 2019. PMID: 31463691 Clinical Trial.
A second target of benzamide riboside: dihydrofolate reductase.
Roussel B, Johnson-Farley N, Kerrigan JE, Scotto KW, Banerjee D, Felczak K, Pankiewicz KW, Gounder M, Lin H, Abali EE, Bertino JR. Roussel B, et al. Among authors: lin h. Cancer Biol Ther. 2012 Nov;13(13):1290-8. doi: 10.4161/cbt.21786. Epub 2012 Sep 6. Cancer Biol Ther. 2012. PMID: 22954684 Free PMC article.
32,360 results
You have reached the last available page of results. Please see the User Guide for more information.